Royalty Pharma buys royalty interests on pharmaceutical drugs, then collects a percentage of sales revenue from those drugs over time. Its customers are essentially drug developers and universities who sell their future royalty streams upfront for cash. Revenue comes entirely from royalty payments tied to drug sales — including products like Imbruvica (blood cancers), Tysabri (multiple sclerosis), and Vertex's cystic fibrosis drugs — without Royalty Pharma manufacturing or selling anything itself.
Employees100IPOSep 17, 2020SIC2833HQ110 East 59th Street, New York, NY, USA, 10022
to
Financials (MXN)
Profitability
Metric
Current
Margins
Gross Margin
—
Operating Margin
62.4%
EBITDA Margin
67.7%
Net Margin
32.1%
OCF Margin
117.5%
FCF Margin
117.5%
Returns on Capital
ROE
12.4%
ROA
4.2%
ROIC
8.6%
ROCE
9.2%
ROC (Greenblatt)
0.0%
3Y ROIIC
19.5%
Consistency
Years Profitable / 10Y
9
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
36.87
Forward P/E
11.31
P/E ex-NRI
39.77
Shiller P/E (CAPE)
—
Cash Flow Multiples
P/FCF
12.18
P/OCF
12.18
P/Owner Earnings
—
FCF Yield
5.81%
Enterprise Value Multiples
EV / EBIT
35.90
EV / Forward EBIT
37.61
EV / EBITDA
35.79
EV / Forward EBITDA
37.61
EV / Revenue
24.21
EV / Forward Revenue
22.91
Asset / Sales
P/S
14.42
P/B
7.59
P/Tangible Book
8.77
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
1.60%
Forward Dividend Yield
1.61%
3Y Dividend Growth
5.0%
Payout Ratio
0.61
5Y Yield on Cost
3.80%
Buybacks & Dilution
3Y Buyback Ratio
1.10%
Combined
Shareholder Yield
−0.25%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
1.31
Gross Debt / EBITDA
5.22
Cash / Debt
0.19
Equity / Assets
0.35
Coverage
Interest Coverage
4.38
Short-Term Liquidity
Current Ratio
2.80
Quick Ratio
2.80
Cash Ratio
2.74
Composite Scores
Piotroski F-Score
5
Altman Z-Score
3.76
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-08-14
$0.235
2026-09-10
2026-05-15
$0.235
2026-06-10
2026-02-20
$0.235
2026-03-10
2025-11-14
$0.22
2025-12-10
2025-08-15
$0.22
2025-09-10
2025-05-16
$0.22
2025-06-10
2025-02-21
$0.22
2025-03-10
2024-11-15
$0.21
2024-12-10
2024-08-16
$0.21
2024-09-13
2024-05-16
$0.21
2024-06-14
10 of 23
View allDate
Transcript
Type
2026-08-05
Q2 2026 Royalty Pharma PLC Earnings Call Transcript
Earnings Call
2026-06-09
Royalty Pharma PLC at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-19
Royalty Pharma PLC at RBC Capital Markets Global Healthcare Conference Transcript
Conference Presentations
2026-05-13
Royalty Pharma PLC at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-05-06
Q1 2026 Royalty Pharma PLC Earnings Call Transcript
Earnings Call
2026-03-03
Royalty Pharma PLC at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-11
Q4 2025 Royalty Pharma PLC Earnings Call Transcript
Earnings Call
2026-01-13
Royalty Pharma PLC at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-03
Royalty Pharma PLC at Evercore ISI Healthcare Conference Transcript
Conference Presentations
2025-12-02
Royalty Pharma PLC at Citi Global Healthcare Conference Transcript
Conference Presentations
10 of 65
5-Step DuPont Analysis
ROE %
12.16%
×
×
Net Margin %
32.42%
×
×
Operating Margin %
62.48%
Operating Income
MX$28.36B
÷
Revenue
MX$45.40B
×
Tax Burden
0.6048
Net Income
MX$14.72B
÷
Pretax Income
MX$24.34B
×
Interest Burden
0.8581
Pretax Income
MX$24.34B
÷
Operating Income
MX$28.36B
×
Asset Turnover
0.13
÷
Revenue
MX$45.40B
÷
Average Total Assets
MX$350.23B
Begin Total Assets
MX$356.14B
End Total Assets
MX$344.32B
×
Equity Multiplier
2.89
÷
Avg Total Assets
MX$350.23B
÷
Avg Stockholders Equity
MX$121.04B
Begin Equity
MX$123.38B
End Equity
MX$118.70B